PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report

Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal disease with limited effective treatment especially after first-line chemotherapy. The human epidermal growth factor receptor 2 (HER-2) immunohistochemistry (IHC) positive is associated with more aggressive clinical behavior and shorter overa...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:World journal of gastroenterology : WJG Ročník 30; číslo 9; s. 1237
Hlavní autori: Kong, Yue-Hong, Xu, Mei-Ling, Zhang, Jun-Jun, Chen, Guang-Qiang, Hong, Zhi-Hui, Zhang, Hong, Dai, Xiao-Xiao, Ma, Yi-Fu, Zhao, Xiang-Rong, Zhang, Chen-Yang, Chen, Rong-Zheng, Xing, Peng-Fei, Zhang, Li-Yuan
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 07.03.2024
Predmet:
Albumins - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Pancreatic Ductal - drug therapy
Deoxycytidine - therapeutic use
Female
Gemcitabine
Humans
Immune Checkpoint Inhibitors - therapeutic use
Paclitaxel - therapeutic use
Pancreatic Neoplasms - drug therapy
Prospective Studies
Receptor, ErbB-2
PRaG 3.0 therapy
Case report
Novel combination therapy
Human epidermal growth factor receptor 2
Pancreatic ductal adenocarcinoma
ISSN:2219-2840, 2219-2840
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal disease with limited effective treatment especially after first-line chemotherapy. The human epidermal growth factor receptor 2 (HER-2) immunohistochemistry (IHC) positive is associated with more aggressive clinical behavior and shorter overall survival in PDAC. We present a case of multiple metastatic PDAC with IHC mismatch repair proficient but HER-2 IHC weakly positive at diagnosis that didn't have tumor regression after first-line nab-paclitaxel plus gemcitabine and PD-1 inhibitor treatment. A novel combination therapy PRaG 3.0 of RC48 (HER2-antibody-drug conjugate), radiotherapy, PD-1 inhibitor, granulocyte-macrophage colony-stimulating factor and interleukin-2 was then applied as second-line therapy and the patient had confirmed good partial response with progress-free-survival of 6.5 months and overall survival of 14.2 month. She had not developed any grade 2 or above treatment-related adverse events at any point. Percentage of peripheral CD8 Temra and CD4 Temra were increased during first two activation cycles of PRaG 3.0 treatment containing radiotherapy but deceased to the baseline during the maintenance cycles containing no radiotherapy. PRaG 3.0 might be a novel strategy for HER2-positive metastatic PDAC patients who failed from previous first-line approach and even PD-1 immunotherapy but needs more data in prospective trials.
Bibliografia:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:2219-2840
2219-2840
DOI:10.3748/wjg.v30.i9.1237